ScreenerHero

ERNAEterna Therapeutics Inc. Common Stock

NAS · US · Healthcare · Biotechnology · ernexatx.com
4.860USD+9.71%Mkt Cap: 5.67M $P/E: —

Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap5.67M $
Enterprise Value2.70M $
Revenue (TTM)—
Gross Profit0 $
Net Income (TTM)-14.08M $
Revenue/Share—
Last Price4.860 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees5
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.47
PEG—
EV/EBITDA-0.23
EV/Revenue—
P/S—
P/B0.59
EPS (TTM)-0.43
EPS (Forward)-9.60
52W Range
3.1802% of range71.50
52W High71.50 USD
52W Low3.180 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-586.59%
ROA-241.41%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-7.02M $
CapEx (TTM)37.00K $
FCF Margin—
FCF Yield-104.60%
Net Debt-4.68M $
Net Debt/EBITDA0.40
Balance Sheet
Debt/Equity0.20
Current Ratio2.01
Quick Ratio1.74
Book Value/Sh7.639 USD
Cash/Share3.080 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:25
Split DateMay 4, 2026
Analyst Consensus
Rating—
Target (Mean)30.00 USD
Upside (mean)+517.3%
Target Range30.00 USD – 30.00 USD
# Analysts1
Ownership
Shares Out.1.17M
Float1.22M
Insiders29.82%
Institutions2.18%
Short Interest
Short Ratio0.0d
Short % Float1.99%
Short % Out.1.25%
Shares Short14.61K
Short (prev mo.)29.38K
Technical
SMA 505.298 (-8.3%)
SMA 20015.04 (-67.7%)
Beta2.56
S&P 52W Chg18.16%
Avg Vol (30d)929.91K
Avg Vol (10d)34.66K
Technical Indicators
RSI (14)52.2
MACD-0.2850
MACD Signal-0.4567
MACD Hist.+0.1717
BB Upper4.938 USD
BB Middle4.071 USD
BB Lower3.203 USD
BB Width42.62%
ATR (14)0.5648 USD
Vol Ratio (20d)1.61x